Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer

  • Technology appraisal guidance
  • TA100
  • Published: 
Download guidance (PDF)

Appendix B. Sources of evidence considered by the committee

The assessment report for this appraisal was prepared by The School of Health and Related Research (ScHARR), University of Sheffield:

  • Pandor A, Eggington S, Paisley S et al. (2005) The use of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer.

The following organisations accepted the invitation to participate in this appraisal. They were invited to make submissions and comment on the draft scope and assessment report and the appraisal consultation document (ACD). Consultee organisations are provided with the opportunity to appeal against the final appraisal determination.

  • Manufacturers/sponsors:

    • Roche Products Ltd

    • Sanofi-Aventis

  • Professional/specialist and patient/carer groups:

    • Association of Coloproctology of Great Britain and Ireland

    • Beating Bowel Cancer

    • Bowel Cancer UK

    • British Oncology Pharmacy Association

    • Cancer Research UK

    • CancerBACUP

    • CORE

    • Department of Health

    • National Council for Palliative Care

    • Royal College of General Practitioners

    • Royal College of Nursing

    • Royal College of Physicians

    • Teenage Cancer Trust

    • Tenovus Cancer Information Centre

    • Welsh Assembly Government

  • Commentator organisations (without the right of appeal):

    • British National Formulary

    • Institute of Cancer Research

    • Medac UK

    • MRC Clinical Trials Unit

    • National Cancer Research Institute

    • National Collaborating Centre for Cancer

    • National Public Health Service for Wales

    • NHS Quality Improvement Scotland

    • Pfizer Ltd

    • Wyeth Pharmaceuticals.

The following individuals were selected from clinical expert and patient advocate nominations from the professional/specialist and patient/carer groups. They participated in the appraisal committee discussions and provided evidence to inform the appraisal committee's deliberations. They gave their expert personal view on oxaliplatin and capecitabine in the adjuvant treatment of stage III (Duke's C) colon cancer by attending the initial committee discussion and/or providing written evidence to the committee. They were also invited to comment on the ACD.

  • Olive Craven, Nurse Clinician, The Christie Hospital NHS Trust – Clinical expert, nominated by Royal College of Nursing

  • Dr Edward Levine, Consultant Clinical Oncologist, The Christie Hospital NHS Trust – Clinical expert, nominated by Association of Coloproctology of Great Britain and Ireland

  • Professor Chris Marks, Consultant Surgeon, The Royal Surrey County Hospital NHS Trust – Clinical expert, nominated by Association of Coloproctology of Great Britain and Ireland

  • Dr Anand Sharma, Consultant Forensic Psychiatrist, The Edenfield Centre – Patient expert.